Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Primary care physicians' attitudes regarding race-based therapies.

Frank D, Gallagher TH, Sellers SL, Cooper LA, Price EG, Odunlami AO, Bonham VL.

J Gen Intern Med. 2010 May;25(5):384-9. doi: 10.1007/s11606-009-1190-7.

2.

Effectiveness of hydralazine/isosorbide dinitrate in racial/ethnic subgroups with heart failure.

Hammermeister KE, Fairclough D, Emsermann CB, Hamman R, Ho M, Phibbs S, Plomondon M, Valuck R, West D, Steiner JF.

Clin Ther. 2009 Mar;31(3):632-43. doi: 10.1016/j.clinthera.2009.03.019.

PMID:
19393854
3.

Influence of patient race on physician prescribing decisions: a randomized on-line experiment.

Rathore SS, Ketcham JD, Alexander GC, Epstein AJ.

J Gen Intern Med. 2009 Nov;24(11):1183-91. doi: 10.1007/s11606-009-1077-7. Epub 2009 Aug 25.

4.

BiDil for heart failure in black patients: The U.S. Food and Drug Administration perspective.

Temple R, Stockbridge NL.

Ann Intern Med. 2007 Jan 2;146(1):57-62.

PMID:
17200223
5.

Flaws in the U.S. Food and Drug Administration's rationale for supporting the development and approval of BiDil as a treatment for heart failure only in black patients.

Ellison GT, Kaufman JS, Head RF, Martin PA, Kahn JD.

J Law Med Ethics. 2008 Fall;36(3):449-57. doi: 10.1111/j.1748-720X.2008.290.x.

6.

Physicians' attitudes toward race, genetics, and clinical medicine.

Bonham VL, Sellers SL, Gallagher TH, Frank D, Odunlami AO, Price EG, Cooper LA.

Genet Med. 2009 Apr;11(4):279-86. doi: 10.1097/GIM.0b013e318195aaf4.

7.

BiDil for heart failure in black patients: implications of the U.S. Food and Drug Administration approval.

Bibbins-Domingo K, Fernandez A.

Ann Intern Med. 2007 Jan 2;146(1):52-6. Erratum in: Ann Intern Med. 2007 Apr 17;146(8):616.

PMID:
17200222
9.

Prescribing BiDil: is it black and white?

Haga SB, Ginsburg GS.

J Am Coll Cardiol. 2006 Jul 4;48(1):12-4. Epub 2006 Jun 9.

10.

The effect of cognitive load and patient race on physicians' decisions to prescribe opioids for chronic low back pain: a randomized trial.

Burgess DJ, Phelan S, Workman M, Hagel E, Nelson DB, Fu SS, Widome R, van Ryn M.

Pain Med. 2014 Jun;15(6):965-74. doi: 10.1111/pme.12378. Epub 2014 Feb 7.

11.

BiDil: assessing a race-based pharmaceutical.

Brody H, Hunt LM.

Ann Fam Med. 2006 Nov-Dec;4(6):556-60.

12.

Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.

Ghali JK, Tam SW, Ferdinand KC, Lindenfeld J, Sabolinski ML, Taylor AL, Worcel M, Curry CL, Cohn JN; A-HeFT Investigators.

Am J Cardiovasc Drugs. 2007;7(5):373-80.

PMID:
18041162
13.

Popular representations of race: the news coverage of BiDil.

Caulfield T, Harry S.

J Law Med Ethics. 2008 Fall;36(3):485-90. doi: 10.1111/j.1748-720X.2008.295.x.

PMID:
18840240
14.

Gray area for new heart failure drug. Although the FDA approved BiDil for blacks with heart failure, it may work in anyone.

[No authors listed]

Harv Heart Lett. 2005 Nov;16(3):1-2. No abstract available.

PMID:
16363036
15.

"Special treatment": BiDil, Tuskegee, and the logic of race.

Reverby SM.

J Law Med Ethics. 2008 Fall;36(3):478-84. doi: 10.1111/j.1748-720X.2008.294.x.

PMID:
18840239
16.

FDA approves heart drug for black patients.

Meadows M.

FDA Consum. 2005 Sep-Oct;39(5):8-9.

17.

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.

Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN; African-American Heart Failure Trial Investigators.

N Engl J Med. 2004 Nov 11;351(20):2049-57. Epub 2004 Nov 8. Erratum in: N Engl J Med. 2005 Mar 24;352(12):1276.

19.

Introduction: Facts and fictions: BiDil and the resurgence of racial medicine.

Dorr GM, Jones DS.

J Law Med Ethics. 2008 Fall;36(3):443-8. doi: 10.1111/j.1748-720X.2008.289.x. No abstract available.

PMID:
18840234
20.

BiDil for heart failure in black patients.

Kahn JD.

Ann Intern Med. 2007 Aug 7;147(3):215; author reply 215-6. No abstract available.

PMID:
17679713
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk